Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 Drug Interaction with Oral Contraceptives
NCT05985590Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 28, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at Day 28 and 1 more. Started Aug 2023; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05985590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985590.